Pipeline
Develop antibody drugs to meet patients' needs
Biocytogen is dedicated to the development of novel antibody drugs to meet the unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s pipeline includes more than 10 assets including monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and striving for clinical excellence, Biocytogen aims to deliver transformative therapies to patients in need.
Clinical pipeline
Therapeutic Area
Product Candidate
Target(s)
Molecular Format
Mono/Combo Therapy
Indication(s)
Development
Preclinical
IND
Phase l
Phase ll
Phase III
Rights
Partner
Oncology
YH002
OX40
mAb
YH003
CD40
mAb
YH004
4-1BB
mAb
YH008
PD-1 x CD40
BsAb
BCG011
TROP2 x EGFR
BsADC
Mono
Oncology
Global MRCT
DOMA
YH013
EGFR x MET
BsADC
Mono
Solid tumors
Global MRCT
DOMA
Clinical pipeline
Oncology
YH001
More
Target(s)：
CTLA-4
Molecular Format：
mAb
Mono/Combo Therapy：
PD-1
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH001
More
Target(s)：
CTLA-4
Molecular Format：
mAb
Mono/Combo Therapy：
Mono
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH002
More
Target(s)：
OX40
Molecular Format：
mAb
Mono/Combo Therapy：
YH003+YH001
Indication(s)：
Intratumoral injection
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Partner：
syncromune
YH003
More
Target(s)：
CD40
Molecular Format：
mAb
Mono/Combo Therapy：
PD-1+ chemo
Indication(s)：
Pancreatic ductal adenocarcinoma (1L&2L)
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH003
More
Target(s)：
CD40
Molecular Format：
mAb
Mono/Combo Therapy：
PD-1+ chemo
Indication(s)：
Mucosal melanoma
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH003
More
Target(s)：
CD40
Molecular Format：
mAb
Mono/Combo Therapy：
PD-1+ YH001
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH004
More
Target(s)：
4-1BB
Molecular Format：
mAb
Mono/Combo Therapy：
Mono
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Global
Partner：
YH008
More
Target(s)：
PD-1 x CD40
Molecular Format：
BsAb
Mono/Combo Therapy：
Mono
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
ex-Greater China
Partner：
Chipscreen NewWay
BCG011
Target(s)：
TROP2 x EGFR
Molecular Format：
BsADC
Mono/Combo Therapy：
Mono
Indication(s)：
Oncology
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Partner：
DOMA
YH013
Target(s)：
EGFR x MET
Molecular Format：
BsADC
Mono/Combo Therapy：
Mono
Indication(s)：
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights：
Partner：
DOMA
Preclinical pipeline
Therapeutic Area
Product Candidate
Target(s)
Molecular Format
Indication(s)
Development
Discovery
Hits
selection
selection
Leads
selection
selection
Candidate
selection
selection
Preclinical
IND
Rights
Partner
Oncology
YH016
Undisclosed
Undisclosed
Oncology
Global
Inflammation and Autoimmunity
YH017
Undisclosed
Undisclosed
Autoimmunity
Global
Oncology
BCG012
HER3 x MUC1
BsADC
Oncology
DOMA
BCG010
NKG2A
mAb
Oncology
ex-Greater China
Undisclosed
BCG006
WT1/HLA-A02×CD3×4-1BB
msAb
Oncology
Global
Undisclosed
BCG013
5T4 x MET
BsADC
Oncology
DOMA
Infectious Diseases
BCG004
Undisclosed
mAb
Infectious diseases
Undisclosed
Rare Diseases
BCG009
Undisclosed
mAb
Rare diseases
ex-Greater China
Undisclosed
Preclinical pipeline
Oncology
YH012
More
Target(s)：
HER2 x TROP2
Molecular Format：
BsADC
Indication(s)：
Solid tumors
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Radiance YH016
Target(s)：
Undisclosed
Molecular Format：
Undisclosed
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights：
Global Inflammation and Autoimmunity
YH015
More
Target(s)：
CD40 inhibitor
Molecular Format：
mAb
Indication(s)：
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights：
Global YH017
Target(s)：
Undisclosed
Molecular Format：
Undisclosed
Indication(s)：
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights：
Global Oncology
BCG003
More
Target(s)：
TNFR2
Molecular Format：
mAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Dragonboatbio Rights：
Global BCG008
More
Target(s)：
SIGLEC15
Molecular Format：
mAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rights：
ex-Greater China BCG012
Target(s)：
HER3 x MUC1
Molecular Format：
BsADC
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
DOMA BCG005
More
Target(s)：
CCR8
Molecular Format：
mAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
LiberoThera Rights：
Global BCG007
More
Target(s)：
AMHR2
Molecular Format：
mAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rights：
Global BCG010
Target(s)：
NKG2A
Molecular Format：
mAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rights：
ex-Greater China BCG006
Target(s)：
WT1/HLA-A02×CD3×4-1BB
Molecular Format：
msAb
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rights：
Global BCG013
Target(s)：
5T4 x MET
Molecular Format：
BsADC
Indication(s)：
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
DOMA Infectious Diseases
BCG004
Target(s)：
Undisclosed
Molecular Format：
mAb
Indication(s)：
Infectious diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rare Diseases
BCG009
Target(s)：
Undisclosed
Molecular Format：
mAb
Indication(s)：
Rare diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner：
Undisclosed Rights：
ex-Greater China 
+86-010-56967680
010-56967601
ir@bbctg.com.cn
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology